GX E2Alternative Names: EPO-hFC; EPO-hybrid Fc; EPO-hyFc; GC-1113; GX-E2; Long-acting EPO; Recombinant erythropoietin long-acting - Genexine/Green Cross
Latest Information Update: 29 Feb 2016
At a glance
- Originator Genexine
- Class Antianaemics; Recombinant erythropoietins; Recombinant fusion proteins
- Mechanism of Action Erythropoiesis stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Anaemia